Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment

Michael A. Markowitz, Bennett S. Levitan, Ateesha F. Mohamed, F. R. Johnson, John F P Bridges, Larry Alphs, Leslie Citrome

Research output: Contribution to journalArticle

Abstract

Objective: The objectives were to quantify psychiatrists' judgments of the benefits and risks of antipsychotic treatments of patients with schizophrenia and to evaluate how patient adherence history affects these judgments. Methods: Weights assigned by respondents to risks, benefits, and alternative drug formulations in the treatment of schizophrenia were assessed via a Web-based survey by using a discrete-choice experiment. Respondents in the United States and the United Kingdom chose among alternative scenarios characterized by various levels of improvement in positive symptoms, negative symptoms, social functioning, weight gain, extrapyramidal symptoms (EPS), hyperprolactinemia, and hyperglycemia and by formulation. The effect of patient adherence history on respondents' judgments was also assessed. Random-parameters logit and bivariate probit models were estimated. Results: The sample included 394 psychiatrists. Improvement in positive symptoms from "no improvement" to "very much improved" was the most preferred outcome over the range of improvements included and was assigned a relative importance score of 10. Other outcomes, in decreasing order of importance, were improvement in negative symptoms from "no improvement" to "very much improved" (5.2; 95% confidence interval [CI]=4.2-6.2), social functioning from "severe problems" to "mild problems" (4.6, CI=3.8-5.4), no hyperglycemia (1.9, CI=1.5-2.4),

Original languageEnglish (US)
Pages (from-to)1133-1139
Number of pages7
JournalPsychiatric Services
Volume65
Issue number9
DOIs
StatePublished - Sep 1 2014

Fingerprint

Antipsychotic Agents
Psychiatry
Schizophrenia
Confidence Intervals
Patient Compliance
Hyperglycemia
History
Drug Compounding
Hyperprolactinemia
Therapeutics
Weight Gain
Weights and Measures
Surveys and Questionnaires

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Medicine(all)

Cite this

Markowitz, M. A., Levitan, B. S., Mohamed, A. F., Johnson, F. R., Bridges, J. F. P., Alphs, L., & Citrome, L. (2014). Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment. Psychiatric Services, 65(9), 1133-1139. https://doi.org/10.1176/appi.ps.201300290

Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment. / Markowitz, Michael A.; Levitan, Bennett S.; Mohamed, Ateesha F.; Johnson, F. R.; Bridges, John F P; Alphs, Larry; Citrome, Leslie.

In: Psychiatric Services, Vol. 65, No. 9, 01.09.2014, p. 1133-1139.

Research output: Contribution to journalArticle

Markowitz, MA, Levitan, BS, Mohamed, AF, Johnson, FR, Bridges, JFP, Alphs, L & Citrome, L 2014, 'Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment', Psychiatric Services, vol. 65, no. 9, pp. 1133-1139. https://doi.org/10.1176/appi.ps.201300290
Markowitz, Michael A. ; Levitan, Bennett S. ; Mohamed, Ateesha F. ; Johnson, F. R. ; Bridges, John F P ; Alphs, Larry ; Citrome, Leslie. / Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment. In: Psychiatric Services. 2014 ; Vol. 65, No. 9. pp. 1133-1139.
@article{946c71f603a94f47917e68eeb18d5002,
title = "Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment",
abstract = "Objective: The objectives were to quantify psychiatrists' judgments of the benefits and risks of antipsychotic treatments of patients with schizophrenia and to evaluate how patient adherence history affects these judgments. Methods: Weights assigned by respondents to risks, benefits, and alternative drug formulations in the treatment of schizophrenia were assessed via a Web-based survey by using a discrete-choice experiment. Respondents in the United States and the United Kingdom chose among alternative scenarios characterized by various levels of improvement in positive symptoms, negative symptoms, social functioning, weight gain, extrapyramidal symptoms (EPS), hyperprolactinemia, and hyperglycemia and by formulation. The effect of patient adherence history on respondents' judgments was also assessed. Random-parameters logit and bivariate probit models were estimated. Results: The sample included 394 psychiatrists. Improvement in positive symptoms from {"}no improvement{"} to {"}very much improved{"} was the most preferred outcome over the range of improvements included and was assigned a relative importance score of 10. Other outcomes, in decreasing order of importance, were improvement in negative symptoms from {"}no improvement{"} to {"}very much improved{"} (5.2; 95{\%} confidence interval [CI]=4.2-6.2), social functioning from {"}severe problems{"} to {"}mild problems{"} (4.6, CI=3.8-5.4), no hyperglycemia (1.9, CI=1.5-2.4),",
author = "Markowitz, {Michael A.} and Levitan, {Bennett S.} and Mohamed, {Ateesha F.} and Johnson, {F. R.} and Bridges, {John F P} and Larry Alphs and Leslie Citrome",
year = "2014",
month = "9",
day = "1",
doi = "10.1176/appi.ps.201300290",
language = "English (US)",
volume = "65",
pages = "1133--1139",
journal = "Psychiatric Services",
issn = "1075-2730",
publisher = "American Psychiatric Association",
number = "9",

}

TY - JOUR

T1 - Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment

AU - Markowitz, Michael A.

AU - Levitan, Bennett S.

AU - Mohamed, Ateesha F.

AU - Johnson, F. R.

AU - Bridges, John F P

AU - Alphs, Larry

AU - Citrome, Leslie

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Objective: The objectives were to quantify psychiatrists' judgments of the benefits and risks of antipsychotic treatments of patients with schizophrenia and to evaluate how patient adherence history affects these judgments. Methods: Weights assigned by respondents to risks, benefits, and alternative drug formulations in the treatment of schizophrenia were assessed via a Web-based survey by using a discrete-choice experiment. Respondents in the United States and the United Kingdom chose among alternative scenarios characterized by various levels of improvement in positive symptoms, negative symptoms, social functioning, weight gain, extrapyramidal symptoms (EPS), hyperprolactinemia, and hyperglycemia and by formulation. The effect of patient adherence history on respondents' judgments was also assessed. Random-parameters logit and bivariate probit models were estimated. Results: The sample included 394 psychiatrists. Improvement in positive symptoms from "no improvement" to "very much improved" was the most preferred outcome over the range of improvements included and was assigned a relative importance score of 10. Other outcomes, in decreasing order of importance, were improvement in negative symptoms from "no improvement" to "very much improved" (5.2; 95% confidence interval [CI]=4.2-6.2), social functioning from "severe problems" to "mild problems" (4.6, CI=3.8-5.4), no hyperglycemia (1.9, CI=1.5-2.4),

AB - Objective: The objectives were to quantify psychiatrists' judgments of the benefits and risks of antipsychotic treatments of patients with schizophrenia and to evaluate how patient adherence history affects these judgments. Methods: Weights assigned by respondents to risks, benefits, and alternative drug formulations in the treatment of schizophrenia were assessed via a Web-based survey by using a discrete-choice experiment. Respondents in the United States and the United Kingdom chose among alternative scenarios characterized by various levels of improvement in positive symptoms, negative symptoms, social functioning, weight gain, extrapyramidal symptoms (EPS), hyperprolactinemia, and hyperglycemia and by formulation. The effect of patient adherence history on respondents' judgments was also assessed. Random-parameters logit and bivariate probit models were estimated. Results: The sample included 394 psychiatrists. Improvement in positive symptoms from "no improvement" to "very much improved" was the most preferred outcome over the range of improvements included and was assigned a relative importance score of 10. Other outcomes, in decreasing order of importance, were improvement in negative symptoms from "no improvement" to "very much improved" (5.2; 95% confidence interval [CI]=4.2-6.2), social functioning from "severe problems" to "mild problems" (4.6, CI=3.8-5.4), no hyperglycemia (1.9, CI=1.5-2.4),

UR - http://www.scopus.com/inward/record.url?scp=84907098261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907098261&partnerID=8YFLogxK

U2 - 10.1176/appi.ps.201300290

DO - 10.1176/appi.ps.201300290

M3 - Article

VL - 65

SP - 1133

EP - 1139

JO - Psychiatric Services

JF - Psychiatric Services

SN - 1075-2730

IS - 9

ER -